Search

Your search keyword '"Díez-Campelo M"' showing total 229 results
Start Over Author "Díez-Campelo M"
229 results on '"Díez-Campelo M"'

1. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

Author

Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R. S., Sekeres, M. A., Della Porta, M. G., Cazzola, M., DeZern, A. E., Roboz, G. J., Steensma, D. P., Van de Loosdrecht, A. A., Schlenk, R. F., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Döhner, H., Platzbecker, U., Pedro, C., Lübbert, M., Oiartzabal, I., Díez-Campelo, M., Cedena, M. T., Machherndl-Spandl, S., López-Pavía, M., Baldus, C. D., Martinez-de-Sola, M., Stauder, R., Merchan, B., List, A., Ganster, C., Schroeder, T., Voso, M. T., Pfeilstöcker, M., Sill, H., Hildebrandt, B., Esteve, J., Nomdedeu, B., Cobo, F., Haas, R., Sole, F., Germing, U., Greenberg, P. L., Haase, D., and Sanz, G.

Published
2021
Full Text
View/download PDF

2. Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.

Author

Zeidan, A.M., Platzbecker, U., Bewersdorf, J.P., Stahl, M., Adès, L., Borate, U., Bowen, D., Buckstein, R., Brunner, A., Carraway, H.E., Daver, N., Díez-Campelo, M., Witte, T.J. de, DeZern, A.E., Efficace, F., Garcia-Manero, G., Garcia, J.S., Germing, U., Giagounidis, A., Griffiths, E.A., Hasserjian, R.P., Hellström-Lindberg, E., Iastrebner, M., Komrokji, R., Kulasekararaj, A.G., Malcovati, L., Miyazaki, Y., Odenike, O., Santini, V., Sanz, G., Scheinberg, P., Stauder, R., Loosdrecht, A.A. van de, Wei, A.H., Sekeres, M.A., Fenaux, P., Zeidan, A.M., Platzbecker, U., Bewersdorf, J.P., Stahl, M., Adès, L., Borate, U., Bowen, D., Buckstein, R., Brunner, A., Carraway, H.E., Daver, N., Díez-Campelo, M., Witte, T.J. de, DeZern, A.E., Efficace, F., Garcia-Manero, G., Garcia, J.S., Germing, U., Giagounidis, A., Griffiths, E.A., Hasserjian, R.P., Hellström-Lindberg, E., Iastrebner, M., Komrokji, R., Kulasekararaj, A.G., Malcovati, L., Miyazaki, Y., Odenike, O., Santini, V., Sanz, G., Scheinberg, P., Stauder, R., Loosdrecht, A.A. van de, Wei, A.H., Sekeres, M.A., and Fenaux, P.

Abstract

Item does not contain fulltext, Myelodysplastic syndromes/myelodysplastic neoplasms (MDS) are associated with variable clinical presentations and outcomes. The initial response criteria developed by the International Working Group (IWG) in 2000 have been used in clinical practice, clinical trials, regulatory reviews, and drug labels. Although the IWG criteria were revised in 2006 and 2018 (the latter focusing on lower-risk disease), limitations persist in their application to higher-risk MDS (HR-MDS) and their ability to fully capture the clinical benefits of novel investigational drugs or serve as valid surrogates for longer-term clinical end points (eg, overall survival). Further, issues related to the ambiguity and practicality of some criteria lead to variability in interpretation and interobserver inconsistency in reporting results from the same sets of data. Thus, we convened an international panel of 36 MDS experts and used an established modified Delphi process to develop consensus recommendations for updated response criteria that would be more reflective of patient-centered and clinically relevant outcomes in HR-MDS. Among others, the IWG 2023 criteria include changes in the hemoglobin threshold for complete remission (CR), the introduction of CR with limited count recovery and CR with partial hematologic recovery as provisional response criteria, the elimination of marrow CR, and specific recommendations for the standardization of time-to-event end points and the derivation and reporting of responses. The updated criteria should lead to a better correlation between patient-centered outcomes and clinical trial results in an era of multiple emerging new agents with novel mechanisms of action.

Published
2023

4. P118 - Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): GENOMIC AND TRANSCRIPTOMIC CHARACTERIZATION OF MYELODYSPLASTIC SYNDROMES/MYELOPROLIFERATIVE NEOPLASMS

Author

Acha, P., Ezponda, T., Vilas-Zornoza, A., Xicoy, B., Palomo, L., Fuster-Tormo, F., Manzanares, A., Zufiaurre, N. Berastegui, Zamora, L., Jerez, A., López-Cadenas, F., Diez-Campelo, M., Bonadies, N., Cervera-Zamora, J., Mascaró, M., Montoro, M.J., Hernández, F., Raya, J.M., Ancín, I., Vahí, M., Garrastazul, M.P., Hermosín-Ramos, M.L., Mallo, M., Grau, J., Marcé, S., Cabezón, M., Prosper, F., and Solé, F.

Published
2023
Full Text
View/download PDF

5. P091 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: A STEP TOWARDS IDENTIFICATION AND CAUSAL INTERPRETATION OF THERAPY-RELATED MDS (T-MDS)

Author

Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., Della Porta, M., Cazzola, M., Dezern, A., Roboz, G., Steensma, D., Van De Loosdrecht, A., Malcovati, L., Schlenk, R., Grau, J., Calvo, X., Blum, S., Pereira, A., Valent, P., Costa, D., Giagounidis, A., Xicoy, B., Döhner, H., Platzbecker, U., Pedro, C., Lübbert, M., Oiartzabal, I., Diez-Campelo, M., Cedena, M.T., Machherndl-Spandl, S., Lopez-Pavia, M., Martinez-De-Sola, M., Stauder, R., Merchan, B., Ganster, C., Schroeder, T., Voso, M.T., Pfeilstöcker, M., Sill, H., Hildebrandt, B., Esteve, J., Cobo, F., Solé, F., Germing, U., Greenberg, P., Haase, D., and Sanz, G.

Published
2023
Full Text
View/download PDF

6. P074 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation/inflammation: BONE MARROW MICROENVIRONMENT CHANGES IN MYELODYSPLASTIC NEOPLASMS AND ITS RELATIONSHIP WITH CLONAL HEMATOPOIESIS

Author

Yordi, A. Molero, Gallur, L., Tazón-Vega, B., Navarro, V., Saumell, S., Montoro, M.J., Salamero, O., González, A. Pérez, Solas, T. Jiménez, López-Cadenas, F., Ezponda, T., Alfonso, A., Altimiras, L., Diez-Campelo, M., Prosper, F., and Valcárcel, D.

Published
2023
Full Text
View/download PDF

8. P052 - Topic: AS04-MDS Biology and Pathogenesis/AS04d-Somatic mutations: TP53 ALLELIC STATE DID NOT INFLUENCE THE PROGNOSIS IN MYELODYSPLASTIC SYNDROMES (MDS) WITH 5Q DELETION

Author

Montoro, M.J., Palomo, L., Haferlach, C., Fuster-Tormo, F., Meggendorfer, M., Xicoy, B., Schulz, F., Della Porta, M., Gonzalez, T., López-Cadenas, F., Acha, P., Diez-Campelo, M., Jerez, A., Such, E., Bernal, T., Santini, V., Platzbecker, U., Germing, U., Solé, F., Haferlach, T., and Valcárcel, D.

Published
2023
Full Text
View/download PDF

10. O10 - CHARACTERIZATION OF TRANSCRIPTIONAL ALTERATIONS LEADING TO ABERRANT MYELOID DIFFERENTIATION IN MYELODYSPLASTIC SYNDROMES

Author

Diaz-Mazkiaran, A., De La Fuente, J., Serrano, G., Ainciburu, M., García-Olloqui, P., Berastegui, N., Alfonso, A., Vilas-Zornoza, A., San-Martin, P., Lamo-Espinosa, J.M., Julián, M. San, Acha, P., Solas, T. Jiménez, López-Cadenas, F., Molero, A., Montoro, M.J., Solé, F., Diez-Campelo, M., Valcárcel, D., Prosper, F., Hernaez, M., and Ezponda, T.

Published
2023
Full Text
View/download PDF

11. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)

Author

Sanoja-Flores, L., Flores-Montero, J., Garcés, J. J., Paiva, B., Puig, N., García-Mateo, A., García-Sánchez, O., Corral-Mateos, A., Burgos, L., Blanco, E., Hernández-Martín, J., Pontes, R., Díez-Campelo, M., Millacoy, P., Rodríguez-Otero, P., Prosper, F., Merino, J., Vidriales, M. B., García-Sanz, R., Romero, A., Palomera, L., Ríos-Tamayo, R., Pérez-Andrés, M., Blanco, J. F., González, M., van Dongen, J. J. M., Durie, B., Mateos, M. V., San-Miguel, J., Orfao, A., and on behalf of the EuroFlow consortium

Published
2018
Full Text
View/download PDF

14. Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion.

Author

Castillo, Martín I., Ribate, Villamón E., Muñoz, Calabuig M., Santillana, Sanz G., Taboada, Such E., Casterá, Mora E., Abinzano, Calasanz M. J., Barranco, Irigoyen A., Nieto, Collado R., Pampliega, Vara M., Blanco, M. L., de Andrés, Álvarez S., de Oteyza, Pérez J., del Castillo, Bernal T., Font, Granada I., Cayuela, Jerez A., Díez‐Campelo, M., Sánchez, Abellán R., Vercet, Solano C., and Díaz, Tormo M.

Subjects
GENETIC mutation, TUMORS, PROGNOSIS
Abstract

Background: In myelodysplastic neoplasms (MDS), the 20q deletion [del(20q)] is a recurrent chromosomal abnormality that it has a high co‐occurrence with U2AF1 mutations. Nevertheless, the prognostic impact of U2AF1 in these MDS patients is uncertain and the possible clinical and/or prognostic differences between the mutation type and the mutational burden are also unknown. Methods: Our study analyzes different molecular variables in 100 MDS patients with isolated del(20q). Results & Conclusions: We describe the high incidence and negative prognostic impact of U2AF1 mutations and other alterations such as in ASXL1 gene to identify prognostic markers that would benefit patients to receive earlier treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. Multicenter Next-Generation Sequencing Studies between Theory and Practice: Harmonization of Data Analysis Using Real-World Myelodysplastic Syndrome Data

Author

Sandmann, S., Graaf, A.O. de, Tobiasson, M., Kosmider, O., Abáigar, M., Clappier, E., Gallì, A., Reijden, B.A. van der, Malcovati, L., Fenaux, P., Díez-Campelo, M., Fontenay, M., Hellström-Lindberg, E., Jansen, J.H., and Dugas, M.

Subjects
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
Abstract

Contains fulltext : 235785.pdf (Publisher’s version ) (Open Access)

Published
2021

17. P756: ALLOGENEIC STEM CELL TRANSPLANTATION IN MYELODYSPLASTIC SYNDROME/MYELOPROLIFERATIVE NEOPLASM (MDS/MPN) OVERLAP SYNDROMES. A SINGLE CENTER EXPERIENCE AND DISSECTION OF MUTATIONAL PROFILE

Author

Avendaño Pita, A., primary, Martín Izquierdo, M., additional, Muntión Olave, S., additional, Jímenez Solas, T., additional, García Antúnez, M., additional, Eva, L., additional, Del Rey, M., additional, Toribio Castelló, S., additional, Yeguas Bermejo, A., additional, González, T., additional, Hernández-Rivas, J. M., additional, Martín López, A. Á., additional, Cabrero, M., additional, Pérez López, E., additional, Cabero, A., additional, Baile, M., additional, Vázquez, L., additional, López Corral, L., additional, Sánchez-Guijo, F., additional, Caballero Barrigon, D., additional, Cortés Rodríguez, M., additional, and Díez Campelo, M., additional

Published
2022
Full Text
View/download PDF

18. P788: FACTORS DRIVING TREATMENT DECISION IN PATIENTS WITH INTERMEDIATE-RISK MYELODYSPLASTIC SYNDROME (MDS): A RETROSPECTIVE ANALYSIS FROM THE GRUPO ESPAÑOL DE SÍNDROMES MIELODISPLÁSICOS SPANISH MDS REGISTRY

Author

Díez-Campelo, M., primary, Hernandez-Donoso, L., additional, Sasse, E., additional, Colicino, S., additional, Curto, J., additional, Molero Yordi, A., additional, Tormo Díaz, M., additional, Arnan, M., additional, Sanz, G., additional, Díaz-Beyá, M., additional, Cedena Romero, M. T., additional, Jerez, A., additional, and Valcárcel Ferreiras, D., additional

Published
2022
Full Text
View/download PDF

19. Immunophenotypic alterations of bone marrow myeloid cell compartments in multiple myeloma patients predict for myelodysplasia-associated cytogenetic alterations

Author

Matarraz, S, Paiva, B, Díez-Campelo, M, Bárrena, S, Jara-Acevedo, M, Gutiérrez, M L, Sayagués, J M, Sánchez, M-L, Bárcena, P, Garrastazul, M P, Berruezo, M J, Duran, J M, Cerveró, C, García-Erce, J A, Florensa, L, Méndez, G D, Gutierrez, O, del Cañizo, M C, van Dongen, J J M, San Miguel, J F, and Orfao, A

Published
2014
Full Text
View/download PDF

23. P30 - Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation: RELATION BETWEEN INMUNE CELL POPULATIONS AND MALIGNANT CLONE MUTATIONAL STATUS IN MYELODYSPLASTIC SYNDROMES

Author

Molero, A., Tazón-Vega, B., Gallur, L., Saumell, S., Solas, T. Jiménez, Ezponda, T., López, F., Altimiras, L., Montoro, J., Sánchez-Ruiz, C., Alfonso, A., Salamero, O., Ortega, M., Perez, A., Peralta, S., Díez-Campelo, M., Prosper, F., Bosch, F., and Valcárcel, D.

Published
2021
Full Text
View/download PDF

24. O29 - Topic: AS02-Epidemiology: COMPARISON OF CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED MDS (T-MDS) AND 4738 PATIENTS FROM THE REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM DATABASE WITH PRIMARY-MDS (P-MDS)

Author

Kuendgen, A., Nomdedeu, M., Tuechler, H., Garcia-Manero, G., Komrokji, R., Sekeres, M., Della Porta, M., Cazzola, M., Malcovati, L., Dezern, A., Roboz, G., Steensma, D., Haase, D., Stauder, R., Cedena, M.T., Van De Loosdrecht, A., Schlenk, R., Blum, S., Grau, J., Calvo, X., Valent, P., Costa, D., Pereira, A., Xicoy, B., Döhner, H., Platzbecker, U., Giagounidis, A., Pedro, C., Lübbert, M., Oiartzabal, I., Díez-Campelo, M., Machherndl-Spandl, S., Lopez-Pavia, M., Martinez-De-Sola, M., Merchan, B., Ganster, C., Schroeder, T., Voso, M.T., Hildebrandt, B., Esteve, J., Nomdedeu, B., Cobo, F., Haas, R., Sole, F., Germing, U., Greenberg, P., Sill, H., Pfeilstöcker, M., and Sanz, G.

Published
2021
Full Text
View/download PDF

25. O20 - Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment: INCORPORATION OF COHESIN MUTATIONAL DATA INTO CURRENT IPSS-R CLASSIFICATION REFINES THE PROGNOSTIC STRATIFICATION OF VERY LOW/LOW-RISK MYELODYSPLASTIC SYNDROMES

Author

Izquierdo, M. Martín, Díez-Campelo, M., Del Real, J. Sánchez, Sánchez, A. Hernández, Sánchez, J.M. Hernández, Janusz, K., López, F., Tormo, M., Megido, M., Olivier, C., Madinaveitia-Ochoa, A., Dávila, J., Sierra, M., Vargas, M., Mínguez, S. Santos, García, C. Miguel, Benito, R., Rivas, J.M. Hernández, Ramos, F., and Abáigar, M.

Published
2021
Full Text
View/download PDF

27. Topic: AS02-Epidemiology

Author

Kuendgen, A., primary, Nomdedeu, M., additional, Tuechler, H., additional, Garcia-Manero, G., additional, Komrokji, R., additional, Sekeres, M., additional, Della Porta, M., additional, Cazzola, M., additional, Malcovati, L., additional, Dezern, A., additional, Roboz, G., additional, Steensma, D., additional, Haase, D., additional, Stauder, R., additional, Cedena, M.T., additional, Van De Loosdrecht, A., additional, Schlenk, R., additional, Blum, S., additional, Grau, J., additional, Calvo, X., additional, Valent, P., additional, Costa, D., additional, Pereira, A., additional, Xicoy, B., additional, Döhner, H., additional, Platzbecker, U., additional, Giagounidis, A., additional, Pedro, C., additional, Lübbert, M., additional, Oiartzabal, I., additional, Díez-Campelo, M., additional, Machherndl-Spandl, S., additional, Lopez-Pavia, M., additional, Martinez-De-Sola, M., additional, Merchan, B., additional, Ganster, C., additional, Schroeder, T., additional, Voso, M.T., additional, Hildebrandt, B., additional, Esteve, J., additional, Nomdedeu, B., additional, Cobo, F., additional, Haas, R., additional, Sole, F., additional, Germing, U., additional, Greenberg, P., additional, Sill, H., additional, Pfeilstöcker, M., additional, and Sanz, G., additional

Published
2021
Full Text
View/download PDF

28. Topic: AS04-MDS Biology and Pathogenesis/AS04i-Microenvironment and stem cell niche

Author

Solas, T. Jiménez, primary, Olave, S. Muntión, additional, López, F., additional, Herrera, R. Ortega, additional, Izquierdo, M. Martín, additional, Martínez, T. González, additional, Janusz, K., additional, Ezponda, T., additional, Vilas, A., additional, Alfonso, A., additional, Prosper, F., additional, Molero, A., additional, Valcárcel, D., additional, Sánchez-Guijo, F., additional, and Díez-Campelo, M., additional

Published
2021
Full Text
View/download PDF

29. Topic: AS06-Prognosis/AS06a-Prognostic factors of outcome and risk assessment

Author

Izquierdo, M. Martín, primary, Díez-Campelo, M., additional, Del Real, J. Sánchez, additional, Sánchez, A. Hernández, additional, Sánchez, J.M. Hernández, additional, Janusz, K., additional, López, F., additional, Tormo, M., additional, Megido, M., additional, Olivier, C., additional, Madinaveitia-Ochoa, A., additional, Dávila, J., additional, Sierra, M., additional, Vargas, M., additional, Mínguez, S. Santos, additional, García, C. Miguel, additional, Benito, R., additional, Rivas, J.M. Hernández, additional, Ramos, F., additional, and Abáigar, M., additional

Published
2021
Full Text
View/download PDF

30. Topic: AS04-MDS Biology and Pathogenesis/AS04h-Immune deregulation

Author

Molero, A., primary, Tazón-Vega, B., additional, Gallur, L., additional, Saumell, S., additional, Solas, T. Jiménez, additional, Ezponda, T., additional, López, F., additional, Altimiras, L., additional, Montoro, J., additional, Sánchez-Ruiz, C., additional, Alfonso, A., additional, Salamero, O., additional, Ortega, M., additional, Perez, A., additional, Peralta, S., additional, Díez-Campelo, M., additional, Prosper, F., additional, Bosch, F., additional, and Valcárcel, D., additional

Published
2021
Full Text
View/download PDF

31. CO77 Impact of Imetelstat Treatment on PROs and Health Care Resource Utilization in Heavily Transfused Non-Del(5Q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis Stimulating Agents: IMerge Phase 3 Trial

Author

Sekeres, M., Santini, V., Diez-Campelo, M., Komrokji, R., Fenaux, P., Savona, M., Madanat, Y., Valcárcel-Ferreiras, D., Illmer, T., Jonášová, A., Bělohlávková, P., Regnault, A., Creel, K., Sengupta, N., Sherman, L., Berry, T., Dougherty, S., Shah, S., Xia, Q., Sun, L., Wan, Y., Huang, F., Ikin, A., Navada, S., Feller, F., Zeidan, A., and Platzbecker, U.

Published
2023
Full Text
View/download PDF

35. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS

Author

Kuendgen, A., primary, Nomdedeu, M., additional, Tuechler, H., additional, Garcia-Manero, G., additional, Komrokji, R. S., additional, Sekeres, M. A., additional, Della Porta, M. G., additional, Cazzola, M., additional, DeZern, A. E., additional, Roboz, G. J., additional, Steensma, D. P., additional, Van de Loosdrecht, A. A., additional, Schlenk, R. F., additional, Grau, J., additional, Calvo, X., additional, Blum, S., additional, Pereira, A., additional, Valent, P., additional, Costa, D., additional, Giagounidis, A., additional, Xicoy, B., additional, Döhner, H., additional, Platzbecker, U., additional, Pedro, C., additional, Lübbert, M., additional, Oiartzabal, I., additional, Díez-Campelo, M., additional, Cedena, M. T., additional, Machherndl-Spandl, S., additional, López-Pavía, M., additional, Baldus, C. D., additional, Martinez-de-Sola, M., additional, Stauder, R., additional, Merchan, B., additional, List, A., additional, Ganster, C., additional, Schroeder, T., additional, Voso, M. T., additional, Pfeilstöcker, M., additional, Sill, H., additional, Hildebrandt, B., additional, Esteve, J., additional, Nomdedeu, B., additional, Cobo, F., additional, Haas, R., additional, Sole, F., additional, Germing, U., additional, Greenberg, P. L., additional, Haase, D., additional, and Sanz, G., additional

Published
2020
Full Text
View/download PDF

36. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

Author

Caballero JC, Sánchez Barba M, Hernández Sánchez JM, Such E, Janusz K, Sanz G, Cabrero M, Chillón C, Cervera J, Hurtado AM, Jerez A, Calderón Cabrera C, Valcárcel D, Lumbreras E, Abáigar M, López Cadenas F, Hernández Rivas JM, Del Cañizo MC, and Díez Campelo M

Subjects
hemic and lymphatic diseases, Allogeneic hematopoietic stem cell transplantation, Chronic graft-versus-host disease, Myelodysplastic syndromes, Somatic mutations, TP53
Abstract

Somatic mutations in patients with myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic stem cell transplantation (HSTC) are associated with adverse outcome, but the role of chronic graft-versus-host disease (cGVHD) in this subset of patients remains unknown. We analyzed bone marrow samples from 115 patients with MDS collected prior to HSCT using next-generation sequencing. Seventy-one patients (61%) had at least one mutated gene. We found that patients with a higher number of mutated genes (more than 2) had a worse outcome (2years overall survival [OS] 54.8% vs. 31.1%, p = 0.035). The only two significant variables in the multivariate analysis for OS were TET2 mutations (p = 0.046) and the development of cGVHD, considered as a time-dependent variable (p 0.001), correlated with a worse and a better outcome, respectively. TP53 mutations also demonstrated impact on the cumulative incidence of relapse (CIR) (1year CIR 47.1% vs. 9.8%, p = 0.006) and were related with complex karyotype (p = 0.003). cGVHD improved the outcome even among patients with more than 2 mutated genes (1-year OS 88.9% at 1year vs. 31.3%, p = 0.02) and patients with TP53 mutations (1-year CIR 20% vs. 42.9%, p = 0.553). These results confirm that cGVHD could ameliorate the adverse impact of somatic mutations in patients with MDS with HSCT.

Published
2019

37. MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS

Author

Martín-Izquierdo, M., primary, López-Cadenas, F., additional, del Real, Sánchez J., additional, Hernández-Sánchez, A., additional, Hernández-Sánchez, J. M., additional, Janusz, K., additional, Lumbreras, E., additional, Díez-Campelo, M., additional, Tormo, M., additional, Megido, M., additional, Olivier, C., additional, Madinaveitia-Ochoa, A., additional, Martín-Nuñez, G., additional, Dávila, J., additional, Aguilar, C., additional, Rodríguez, J. N., additional, Alonso, J. M., additional, Sierra, M., additional, Vargas, M., additional, Santos-Mínguez, S., additional, Miguel-García, C., additional, Benito, R., additional, Hernández-Rivas, J. M., additional, Ramos, F., additional, and Abáigar, M., additional

Published
2019
Full Text
View/download PDF

38. S837 TREATMENT WITH IMETELSTAT PROVIDES DURABLE TRANSFUSION INDEPENDENCE (TI) IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER RISK MDS (LR-MDS) RELAPSED/REFRACTORY (R/R) TO ERYTHROPOIESIS STIMULATING AGENTS (ESAS)

Author

Fenaux, P., primary, Steensma, D.P., additional, Van Eygen, K., additional, Raza, A., additional, Santini, V., additional, Germing, U., additional, Font, P., additional, Díez-Campelo, M., additional, Thepot, S., additional, Vellenga, E., additional, Patnaik, M.M., additional, Jang, J.H., additional, Sherman, L., additional, Sun, L., additional, Varsos, H., additional, Rizo, A., additional, Wan, Y., additional, Huang, F., additional, Bussolari, J., additional, Rose, E., additional, and Platzbecker, U., additional

Published
2019
Full Text
View/download PDF

39. PF541 TRANSCRIPTIONAL ALTERATIONS OF HEMATOPOIETIC STEM CELLS IN MYELODYSPLASTIC SYNDROMES

Author

Ezponda, T., primary, Romero, J.P., additional, Ainciburu, M., additional, Alfonso, A., additional, Vilas, A., additional, Martín, P. San, additional, Castro, L., additional, Jiménez, T., additional, López, F., additional, Hernández, J., additional, Molero, A., additional, Montoro, J., additional, Tazón, B., additional, Paiva, B., additional, Díez-Campelo, M., additional, Valcárcel, D., additional, Miguel, J. San, additional, Lara, D., additional, and Prósper, F., additional

Published
2019
Full Text
View/download PDF

40. PF533 MUTATIONS ON COHESIN COMPLEX ARE ASSOCIATED TO A POOR PROGNOSIS IN LOW-RISK MYELODYSPLASTIC SYNDROMES PATIENTS

Author

Martín-Izquierdo, M., primary, López-Cadenas, F., additional, Sánchez del Real, J., additional, Hernández-Sánchez, A., additional, Hernández-Sánchez, J.M., additional, Janusz, K., additional, Lumbreras, E., additional, Díez-Campelo, M., additional, Tormo, M., additional, Megido, M., additional, Olivier, C., additional, Madinaveitia-Ochoa, A., additional, Martín-Nuñez, G., additional, Dávila, J., additional, Aguilar, C., additional, Rodríguez, J.N., additional, Alonso, J.M., additional, Sierra, M., additional, Vargas, M., additional, Santos-Mínguez, S., additional, Miguel-García, C., additional, Benito, R., additional, Hernández-Rivas, J.M., additional, Ramos, F., additional, and Abáigar, M., additional

Published
2019
Full Text
View/download PDF

42. TRANSCRIPTIONAL ALTERATIONS OF HEMATOPOIETIC STEM CELLS IN MYELODYSPLASTIC SYNDROMES

Author

Ezponda, T., primary, Romero, J. P., additional, Ainciburu, M., additional, Alfonso, A., additional, Vilas, A., additional, San Martín, P., additional, Castro, L., additional, Jiménez, T., additional, López, F., additional, Hernández, J., additional, Molero, A., additional, Montoro, J., additional, Tazón, B., additional, Paiva, B., additional, Díez-Campelo, M., additional, Valcárcel, D., additional, San Miguel, J., additional, Lara, D., additional, and Prósper, F., additional

Published
2019
Full Text
View/download PDF

43. 41 - Chronic GVHD Could Ameliorate the Impact of Adverse Somatic Mutations in Patients with Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation

Author

Caballero Berrocal, J.C., Sánchez Barba, M., Hernández Sánchez, J.M., Del Rey, M., Janusz, K., Chillón, C., Such, E., Sanz, G., Hurtado, A.M., Calderón Cabrera, C., Valcárcel, D., Lumbreras, E., Robledo, C., Abáigar, M., López Cadenas, F., Cabrero, M., Redondo-Guijo, A., Hernández Rivas, J.M., Del Cañizo, M.C., and Díez Campelo, M.

Published
2017
Full Text
View/download PDF

44. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes

Author

Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, and Florensa L

Subjects
hemic and lymphatic diseases
Abstract

Erythroleukemia was considered an acute myeloid leukemia in the 2008 World Health Organization (WHO) classification and is defined by the presence of >= 50% bone marrow erythroblasts, having = 20% bone marrow myeloblasts from nonerythroid cells. Erythroleukemia shares clinicopathologic features with myelodysplastic syndromes, especially with erythroid-predominant myelodysplastic syndromes (>= 50% bone marrow erythroblasts). The upcoming WHO revision proposes to eliminate the nonerythroid blast cell count rule and to move erythroleukemia patients into the appropriate myelodysplastic syndrome category on the basis of the absolute blast cell count. We conducted a retrospective study of patients with de novo erythroleukemia and compared their clinico-biological features and outcome with those of de novo myelodysplastic syndromes, focusing on erythroid-predominant myelodysplastic syndromes. Median overall survival of 405 erythroid-predominant myelodysplastic syndromes without excess blasts was significantly longer than that observed in 57 erythroid-predominant refractory anemias with excess blasts-1 and in 59 erythroleukemias, but no significant difference was observed between erythroid-predominant refractory anemias with excess blasts-1 and erythroleukemias. In this subset of patients with >= 50% bone marrow erythroblasts and excess blasts, the presence of a high-risk karyotype defined by the International Prognostic Scoring System or by the Revised International Prognostic Scoring System was the main prognostic factor. In the same way, the survival of 459 refractory anemias with excess blasts-2, independently of having >= 20% bone marrow blasts from nonerythroid cells or not, was almost identical to the observed in 59 erythroleukemias. Interestingly, 11 low-blast count erythroleukemias with 5 to < 10% bone marrow blasts from total nucleated cells showed similar survival than the rest of erythroleukemias. Our data suggest that de novo erythroleukemia is in the spectrum of myelodysplastic syndromes with excess blasts and support its inclusion into future classifications of myelodysplastic syndromes.

Published
2016

45. Chronic GVHD Could Ameliorate the Impact of Adverse Somatic Mutations in Patients with Myelodysplastic Syndromes and Hematopoietic Stem Cell Transplantation

Author

Caballero Berrocal, J.C., primary, Sánchez Barba, M., additional, Hernández Sánchez, J.M., additional, Del Rey, M., additional, Janusz, K., additional, Chillón, C., additional, Such, E., additional, Sanz, G., additional, Hurtado, A.M., additional, Calderón Cabrera, C., additional, Valcárcel, D., additional, Lumbreras, E., additional, Robledo, C., additional, Abáigar, M., additional, López Cadenas, F., additional, Cabrero, M., additional, Redondo-Guijo, A., additional, Hernández Rivas, J.M., additional, Del Cañizo, M.C., additional, and Díez Campelo, M., additional

Published
2017
Full Text
View/download PDF

46. Mutational Status of Mesenchymal Stem Cell in Myelodysplastic Syndromes Patients

Author

Janusz, K., primary, Muntion, S., additional, Hernández-Sánchez, J.M., additional, Izquierdo, M. Martín, additional, Hernández-Sánchez, M., additional, Abáigar, M., additional, Robledo, C., additional, López-Cadenas, F., additional, del Rey, M., additional, Caballero, J.C., additional, Benito, R., additional, Guijo, A. Redondo, additional, Jimenez, T., additional, Sánchez-Guijo, F., additional, del Cañzo, C., additional, Díez-Campelo, M., additional, and Hernández-Rivas, J.M., additional

Published
2017
Full Text
View/download PDF

47. Mutational and Clonal Dynamics During Progression from MDS to SAML by Whole-Exome and Targeted-Deep Sequencing

Author

Martín Izquierdo, M., primary, Abáigar, M., additional, Hernández-Sánchez, J.M., additional, Tamborero, D., additional, Díez-Campelo, M., additional, Hernández-Sánchez, M., additional, Ramos, F., additional, Megido, M., additional, Aguilar, C., additional, Lumbreras, E., additional, Redondo-Guijo, A., additional, Recio, I., additional, Olivier, C., additional, Benito, R., additional, López-Bigas, N., additional, del Cañizo, M.C., additional, and Hernández-Rivas, J.M., additional

Published
2017
Full Text
View/download PDF

48. Sintra-Rev Clinical Trial: Preliminary Analysis of Efficacy and Safety at Week 12 of Treatment in MDS Del(5Q) and Transfusion Independence

Author

López Cadenas, F., primary, Xicoy, B., additional, Sánchez, J., additional, Fenaux, P., additional, Hernández Rivas, J.Á., additional, Amigo, M.L., additional, Coll, R., additional, Lumbreras, E., additional, Slama, B., additional, Bernal, T., additional, De Paz, R., additional, Platzbecker, U., additional, Giagounidis, A., additional, Nomdedeu, B., additional, Thepot, S., additional, Sanz, G., additional, Arrizabalaga, B., additional, Bargay, J., additional, Del Cañizo Fernández-Roldán, M.C., additional, and Díez-Campelo, M., additional

Published
2017
Full Text
View/download PDF

49. What is the Outcome of Patients in the Intermediate IPSS-R Score Group? Spanish Approach for Better Stratification with Classical Tools

Author

Guijo, A.M. Redondo, primary, Sánchez-Barba, M., additional, Santillana, G. Sanz, additional, Bernal, T., additional, Sangerman, M. Arnan, additional, Ortega, F. Ramos, additional, Olivé, C. Pedro, additional, Lozano, M.L. Amigo, additional, Betes, V. Marco, additional, Valcárcel, D., additional, Ardanaz, M., additional, Brunet, S., additional, Lleonart, J. Bargay, additional, Tormo, M., additional, Xicoy, B., additional, Nomdedeu, M., additional, Cadenas, F. López, additional, Berrocal, J.C. Caballero, additional, Cañizo, M.C.D., additional, and Díez-Campelo, M., additional

Published
2017
Full Text
View/download PDF

50. DNA Repair Genes Transcriptome in Chronic Myelomonocytic Leukemia

Author

Hurtado, A.M., primary, Luengo-Gil, G., additional, Chen-Liang, T.H., additional, Palomo, L., additional, Lumbreras, E., additional, Przychodzen, B., additional, Amigo, M.L., additional, Díez-Campelo, M., additional, Zamora, L., additional, Ortuño, F., additional, Vicente, V., additional, Maciejewski, J., additional, del Cañizo, C., additional, Solé, F., additional, Ferrer-Marín, F., additional, and Jerez, A., additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results